Original Research and the Latest News
Recent Posts
The Obesity Drug Pipeline in 2026: Emerging Targets, Companies and Clinical Readouts
The Obesity Drug Pipeline in 2026 Obesity drug development is expanding rapidly beyond the first generation of GLP-1 therapies....
Why Clinical Trial Data Belongs in Every Pharma Valuation Model
Financial statements show how much pharmaceutical companies spend. Clinical trial data reveals whether that investment is...
OZMOSI Announces Strategic Partnership with Planview to Advance AI-Driven Planning in Pharmaceutical R&D
By combining structured clinical intelligence with AI-driven portfolio planning, the partnership gives pharmaceutical teams a...
Pharmaceutical Portfolio Strategy in the AI Era: Why External Intelligence Matters
A Joint Whitepaper by Planview and Ozmosi Executive Summary Pharmaceutical portfolio strategy is entering a new era. For...
Why AI Stalls in Pharmaceutical R&D Operations (and How to Fix It)
Artificial intelligence has become a fixture in pharmaceutical strategy conversations. Nearly every major organization has...
Who is Winning in Innovation and How are They Balancing Risk?
Examining the innovation-to-risk balance among the pharmaceutical industry’s top companies In our previous post, we evaluated...
How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%
Unlocking Next-Gen POS Forecasting for Biopharma Success In the high-stakes world of biopharma, advanced Probability of Success...
Market Overview: GLP-1 Agonists and the Obesity Market
Introduction to GLP-1 AgonistsGLP-1 agonists have been pivotal in the pharmaceutical market for nearly two decades, beginning...
Not Your Grandparents’ Probability of Success Forecasts
Redefining Probability of Success in Pharma: A Data-Driven Revolution In the world of pharmaceutical strategic planning and...
Who’s Winning the Pharmaceutical R&D Pipeline Race in 2025
The leaders, the contenders, and the strategies for success As we approach the 4th quarter of 2025, let’s review where the...
7 Small-Cap Biotech Companies to Watch at AACR in April
We anticipate scientific reviews and clinical trial updates from 40 companies on nearly 80 oncology development programs at the...
Clinical Trial Success Rates: What Makes Some Companies Stand Out?
Our comprehensive analysis of over 30,000 clinical trials across more than 4,000 biopharmaceutical companies reveals significant...
Uncovering New Catalyst Events in the Pharmaceutical and Biotech Markets
The Challenges with Predicting Catalyst Events “Chasing headlines” for catalyst events in the biotech and pharmaceutical markets...
Finding the Needle in a Haystack with NLP
The problem with Big Data is that it is so Big! This issue is especially true in the world of healthcare and drug development. ...
Using Data to Optimize Clinical Trial Recruitment
The Importance of a High-Performing Clinical Trial Partnership Pharmaceutical companies are heavily dependent on clinical trials...
Healthiest States Index of The USA 2024
Health and wellness are pivotal for leading a wholesome life. Good health is a blessing. Time and health are the two most...
FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations Supercharge Drug Development
FDA Expedited Drug Development Programs The Food and Drug Administration (FDA) follows an established and lengthy approval...
New Developments in Alzheimer’s Treatment
OZMOSI’s predictions for where Alzheimer's treatment is headed. The Ravaging Effects of Alzheimer’s The devastation of living...
Recent Tweets
Get Started with OZMOSI
We synthesize and process insights, delivering what you need quickly, effectively, and efficiently.
600 Warren Ave,
Spring Lake, NJ 07762